May 30, 2013 — Pharmax announced that the Federal Canadian health department, Health Canada has approved two significant claims related to its proprietary human lactic commensal (HLC) probiotics, HLC Intensive and HLC Replenish.
“Considering that few products in the market target these specific conditions, we are pleased to receive Health Canada’s approval for the two claims related to the treatment of IBS and to post-antibiotic recovery. This is another example of our ongoing commitment to incorporate safe and effective formulas that reflect the latest evidence-based research. Under the direction of Dr. Nigel Plummer, Pharmax HLC strains were meticulously selected and diligently tested in double-blind, placebo controlled clinical trials,” said Yves Yau, president at Seroyal.
The double-blind, placebo controlled Sheffield IBS Trial tested four strains of high potency human lactic commensal probiotics and concluded that Pharmax’s proprietary HLC blend indeed proved effective, decreasing the severity of IBS symptoms and number of days with pain, while improving satisfaction with bowel habits and overall quality of life. The trial was published in Alimentary Pharmacology & Therapeutics.
The Cambridge Probiotic/Antibiotic Clinical Trial revealed that Pharmax’s proprietary HLC blend offers proven post-antibiotic replenishment and care by promoting a healthy microflora. The trial was published in the International Journal of Antimicrobial Agents.
“Pharmax’s human-derived probiotic strains more easily survive the rigours of the intestinal environment and are more efficient at colonizing the intestinal lining – ultimately yielding greater benefits” said Plummer.
Source: Pharmax, seroyal.com
